Neuphoria Therapeutics (NEUP) Change in Cash (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Change in Cash for 4 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Change in Cash fell 122.12% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 73.06% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, up 217.18% from the prior year.
• Change in Cash was -$2.8 million for Q1 2026 at Neuphoria Therapeutics, down from $8.5 million in the prior quarter.
• Over five years, Change in Cash peaked at $12.7 million in Q1 2025 and troughed at -$4.5 million in Q3 2024.
• A 4-year average of $659882.8 and a median of -$1.7 million in 2024 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash slumped 300.16% in 2024 and jumped 833.07% in 2025, its largest moves.
• Over 4 years, Change in Cash stood at $1.9 million in 2023, then slumped by 300.16% to -$3.7 million in 2024, then surged by 327.47% to $8.5 million in 2025, then sank by 132.97% to -$2.8 million in 2026.
• The last three Change in Cash figures came in at -$2.8 million (Q1 2026), $8.5 million (Q4 2025), and -$560488.0 (Q3 2025), per Business Quant data.